Sonam Puri, MD, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, discusses the testing procedures for the two types of non-small cell lung cancer (NSCLC). Dr. Puri speaks on the value of broad-based DNA/RNA molecular testing on any patient with metastatic adenocarcinoma at the time of diagnosis. However, this testing is limited for patients with early-stage disease. For squamous cell lung cancer, a PD-L1 test is conducted which acts as a biomarker for immunotherapy response. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.